329 related articles for article (PubMed ID: 16960105)
21. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Ross Eckard A; Longenecker CT; Jiang Y; Debanne SM; Labbato D; Storer N; McComsey GA
HIV Med; 2014 Oct; 15(9):537-46. PubMed ID: 24650269
[TBL] [Abstract][Full Text] [Related]
23. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
24. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
Shi Y; Zhang P; Zhang L; Osman H; Mohler ER; Macphee C; Zalewski A; Postle A; Wilensky RL
Atherosclerosis; 2007 Mar; 191(1):54-62. PubMed ID: 16765356
[TBL] [Abstract][Full Text] [Related]
25. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
26. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
27. Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions: a cross-sectional study.
Wang X; Chen Q; Xu Y; Wang Y; Yang Y; Gu M; Xu H; Zhao Y
Lipids Health Dis; 2017 Mar; 16(1):63. PubMed ID: 28335787
[TBL] [Abstract][Full Text] [Related]
28. Sudden coronary death caused by pathologic intimal thickening without atheromatous plaque formation.
Tavora F; Cresswell N; Li L; Ripple M; Fowler D; Burke A
Cardiovasc Pathol; 2011; 20(1):51-7. PubMed ID: 19913444
[TBL] [Abstract][Full Text] [Related]
29. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Li J; Zhou Z; Niu X; Li H
Clin Lab; 2020 May; 66(5):. PubMed ID: 32390386
[TBL] [Abstract][Full Text] [Related]
31. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
Koenig W; Twardella D; Brenner H; Rothenbacher D
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
[TBL] [Abstract][Full Text] [Related]
32. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Ikonomidis I; Kadoglou NN; Tritakis V; Paraskevaidis I; Dimas K; Trivilou P; Papadakis I; Tzortzis S; Triantafyllidi H; Parissis J; Anastasiou-Nana M; Lekakis J
Atherosclerosis; 2014 May; 234(1):34-41. PubMed ID: 24594367
[TBL] [Abstract][Full Text] [Related]
33. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Sudhir K
J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans.
Yang EH; McConnell JP; Lennon RJ; Barsness GW; Pumper G; Hartman SJ; Rihal CS; Lerman LO; Lerman A
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):106-11. PubMed ID: 16239595
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein-associated phospholipase A2 regulates macrophage apoptosis via the Akt and caspase-7 pathways.
Maeda T; Takeuchi K; Xiaoling P; P Zankov D; Takashima N; Fujiyoshi A; Kadowaki T; Miura K; Ueshima H; Ogita H
J Atheroscler Thromb; 2014; 21(8):839-53. PubMed ID: 24717759
[TBL] [Abstract][Full Text] [Related]
36. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
37. Immunolocalisation of fibrin in coronary atherosclerosis: implications for necrotic core development.
Tavora F; Cresswell N; Li L; Ripple M; Burke A
Pathology; 2010 Jan; 42(1):15-22. PubMed ID: 20025475
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Tselepis AF; Rizzo M; Goudevenos IA
Curr Pharm Des; 2011 Nov; 17(33):3656-61. PubMed ID: 22074435
[TBL] [Abstract][Full Text] [Related]
39. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
Albert MA; Glynn RJ; Wolfert RL; Ridker PM
Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658
[TBL] [Abstract][Full Text] [Related]
40. Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Dohi T; Miyauchi K; Ohkawa R; Nakamura K; Thuboi S; Ogita M; Miyazaki T; Nishino A; Yokoyama K; Kurata T; Yatomi Y; Daida H
Ann Clin Biochem; 2012 Nov; 49(Pt 6):527-33. PubMed ID: 22933444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
